222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details
臨床試験数 : 285 / 薬物数 : 285 - (DrugBank : 108) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-001212-29-DK (EUCTR) | 26/08/2020 | 09/06/2020 | Causes and prevention of thrombosis developed due to the kidney disease nephrotic syndrome | Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome | Nephrotic syndrome is defined as severe proteinuria (> 0.5 g / day), edema and hypoalbuminemia. It is conditioned by a defect in the kidney's glomerular filtration barrier, resulting in the loss of a large number of plasma proteins including coagulation factors and consequently a increased risk of thromboembolic complications. The most frequent cause of nephrotic syndrome is the renal disease membranous nephropathy, which is associated with the greatest risk of thromboembolic complications. MedDRA version: 21.1;Level: LLT;Classification code 10029167;Term: Nephrotic syndrome with lesion of membranous glomerulonephritis;System Organ Class: 100000004857 MedDRA version: 20.0;Classification code 10029165;Term: Nephrotic syndrome in diseases classified elsewhere;System Organ Class: 100000004857;Therapeutic area: Not possible to specify | Trade Name: Fragmin INN or Proposed INN: Dalteparin Other descriptive name: Dalteparin Trade Name: Eliquis INN or Proposed INN: Apixaban Other descriptive name: Apixaban | Aarhus University Hospital, Henrik Birn | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 70 | Phase 1;Phase 2 | Denmark |